Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23975826 | 0.85 | KDM4C (0.52) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL30275470 | 0.84 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25918360 | 0.82 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL14065688 | 0.79 | KDM4C (0.51) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL14228817 | 0.78 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL1422310 | 0.75 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL6879618 | 0.75 | KDM4C (0.58) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL9827131 | 0.74 | DHFR (0.44) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL1800977 | 0.74 | KDM4C (0.51) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL13953759 | 0.74 | KDM4C (0.51) | KDM4CNPC1RAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | KDM4C 4507/4885NPC1 897/4885RAB9A 2710/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | KDM4C 4818/4885NPC1 389/4885RAB9A 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.